Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $648,000.

  • Arcturus Therapeutics Holdings' Capital Expenditures rose 126.25% to $181,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $726,000, marking a year-over-year decrease of 52.33%. This contributed to the annual value of $648,000 for FY2024, which is 77.66% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Capital Expenditures of $648,000 as of FY2024, which was down 77.66% from $2.9 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' 5-year Capital Expenditures high stood at $7.7 million for FY2022, and its period low was $648,000 during FY2024.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median Capital Expenditures value was $2.9 million (recorded in 2023), while the average stood at $3.8 million.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Capital Expenditures surged by 126.83% in 2022 and then tumbled by 77.66% in 2024.
  • Arcturus Therapeutics Holdings' Capital Expenditures (Yearly) stood at $1.7 million in 2020, then surged by 95.52% to $3.4 million in 2021, then skyrocketed by 126.83% to $7.7 million in 2022, then tumbled by 62.45% to $2.9 million in 2023, then plummeted by 77.66% to $648,000 in 2024.